0001437749-19-000614.txt : 20190109 0001437749-19-000614.hdr.sgml : 20190109 20190109170022 ACCESSION NUMBER: 0001437749-19-000614 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20190109 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20190109 DATE AS OF CHANGE: 20190109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DiaMedica Therapeutics Inc. CENTRAL INDEX KEY: 0001401040 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: Z4 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36291 FILM NUMBER: 19518691 BUSINESS ADDRESS: STREET 1: 2 CARLSON PARKWAY STREET 2: SUITE 260 CITY: MINNEAPOLIS STATE: MN ZIP: 55447 BUSINESS PHONE: (763) 496-5454 MAIL ADDRESS: STREET 1: 2 CARLSON PARKWAY STREET 2: SUITE 260 CITY: MINNEAPOLIS STATE: MN ZIP: 55447 FORMER COMPANY: FORMER CONFORMED NAME: DiaMedica Inc. DATE OF NAME CHANGE: 20070525 8-K 1 dmtp20190108_8k.htm FORM 8-K dmtp20190108_8k.htm

 



UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

__________________

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

__________________

 

Date of Report (Date of earliest event reported): January 9, 2019

___________________

 

diamedica therapeutics inc.

(Exact name of registrant as specified in its charter)

 

Canada

001-36291

Not Applicable

(State or other jurisdiction of

incorporation)

(Commission File Number)

(I.R.S. Employer

Identification Number)

 

2 Carlson Parkway, Suite 260

Minneapolis, Minnesota

 

55447

(Address of principal executive offices)

(Zip Code)

 

(763) 496-5454

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

 

Emerging growth company ☒                      

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒

 



 

 

 

 

Item 3.01            Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

 

Effective on January 9, 2019, the Board of Directors of DiaMedica Therapeutics Inc., a business corporation governed by the Canada Business Corporations Act (the “Company”), approved an application to the TSX Venture Exchange (the “TSXV”) to voluntarily delist from trading the Company’s common shares on the TSXV. Given the recent listing of the Company’s common shares on The Nasdaq Capital Market in connection with its December 2018 initial public offering of its common shares in the United States, the Company believes that the financial and administrative costs associated with maintaining a dual listing are not justified. The Company expects that its voluntary delisting application will be effective at market close on January 18, 2019, and the Company’s common shares will no longer be traded through the facilities of the TSXV. The Company’s common shares are currently traded, and will continue to trade, on The Nasdaq Capital Market under the symbol “DMAC”.

 

A copy of the Company’s press release announcing the voluntary delisting of its common shares from the TSXV is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01            Financial Statements and Exhibits.

 

(d)   Exhibits.

 

Exhibit No.

 

Description

99.1

 

Press release dated January 9, 2019 announcing voluntary delisting of common shares from the TSX Venture Exchange

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

DIAMEDICA THERAPEUTICS INC.

 

     

 

 

 

 

 

 

 

 

 

By:

/s/ Scott Kellen

 

 

 

Scott Kellen

 

 

 

Chief Financial Officer and Secretary

 

 

Dated: January 9, 2019 

EX-99.1 2 ex_132625.htm EXHIBIT 99.1 ex_132625.htm

Exhibit 99.1

 

 

DiaMedica Therapeutics Announces Voluntary Delisting from TSX Venture Exchange

 

Minneapolis, Minnesota, January 9, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) (TSX-V: DMA), a clinical stage biopharmaceutical company, announced today that it has applied to voluntarily delist its voting common shares from the TSX Venture Exchange.

 

The Company’s common shares are expected to be delisted from the TSX-V at the close of business on January 18, 2019, being approximately 10 days from today's date. DiaMedica’s shares will continue to be listed for trading on The Nasdaq Capital Market (“Nasdaq”) under the trading symbol “DMAC.” The Company believes that the continued listing of its common shares on the Nasdaq will provide its Canadian shareholders with a sufficiently liquid market and further, that the financial and administrative costs associated with maintaining a dual listing are not justified.

 

About DiaMedica

 

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing novel treatments for neurological and kidney diseases. DiaMedica’s shares are listed on The Nasdaq Capital Market under the trading symbol “DMAC.”

 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

 

IR Contact:

Paul Papi
Vice President of Business Development
2 Carlson Parkway, Suite 260
Minneapolis, MN  55447
(617) 899-5941
info@diamedica.com

GRAPHIC 3 a1.jpg begin 644 a1.jpg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end